Syra Health, a healthcare technology company that provides tools to analyze population health, reported a total revenue of $2 million in the second quarter of 2024 compared to $1 million in the same period last year. Its Population Health unit comprised 28% of the company’s total revenue in Q2 2024, growing 347% at the end […]
UK-based healthcare technology company Huma announced it secured more than $80 million in a Series D funding round, bringing its total raise to over $300 million. New and existing investors, including AstraZeneca, Leaps by Bayer, Hat Technology Fund 4 by HAT SGR, and HV Fund by Hitachi Ventures, participated in the round. The company, which
Digital health tech company Huma scores $80M and more digital health raises Read More »
Syra Health, a healthcare technology company that provides tools to analyze population health, reported revenue of $1.7 million in the first quarter of 2024, compared to $1.2 million in the same period last year. The company noted that its strong growth was due to its Population Health offering, which grew 212% year over year, and
Syra Health reports 47% revenue growth YOY and more digital health earnings Read More »
Conversational AI organization Openstream.ai announced a new patent for automated digital twin technology that gives EVA, or enterprise virtual assistant, users the ability to utilize virtual assistants that are digital twins of human experts in their respective fields. The digital twins share their human counterparts’ knowledge and unique personas and engage in empathetic, hallucination-free conversations
Openstream.ai notches patent for multimodal AI-driven digital twin Read More »
Indian AI drug discovery firm gets $1M to focus on rare diseases Peptris Technologies from Bangalore, India has received $1 million in pre-seed funding in a round led by Speciale Invest. In a statement, the AI-driven drug discovery company said it will use its fresh funds to expand its research scope to cover rare diseases,
$1M funding for AI drug discovery for rare diseases and more digital health fundings Read More »
Leaders in the digital health space relayed to MobiHealthNews what stood out to them in 2023 as the year draws to an end. Many noted the meteoric rise of genAI in 2023 and expectations of growing adoption of the technology in 2024, emphasizing the importance of treading carefully as the tech is further implemented. Other
Digital health leaders discuss their biggest takeaways from 2023 Read More »
The Access to Prescription Digital Therapeutics Act, initially introduced in the U.S. Senate in 2022 and reintroduced in March of this year, aims to amend the Social Security Act to provide Medicare and Medicaid coverage and reimbursement for prescription digital therapeutics. Jennifer Mathieu, senior vice president of professional and government affairs at the Academy of
Q&A: The status of the Access to Prescription Digital Therapeutics Act Read More »
2023 will be known, sadly, as the year millions of Americans were removed from Medicaid. As states reset their Medicaid eligibility rules post-pandemic, more rapid “unwinding” out of the gate is being seen than was predicted. Even though the public health emergency, which guaranteed continuous coverage for enrollees, just ended in May, 1,625,000 people on
QuantHealth, an Israeli AI-enabled clinical trial design startup, announced David Dornstreich is joining the company as its general manager and chief commercial officer of U.S. operations, marking its entry into the U.S. market. Dornstreich previously held the role of senior vice president of business development at healthcare data company ConcertAI, vice president of strategic initiatives
QuantHealth hires former ConcertAI, Allscripts leader and more digital health hires Read More »
CHICAGO — During the Venture Connect panel on demystifying digital therapeutics at the 2023 HIMSS Global Health Conference & Exhibition here on Tuesday, panelists provided insights into the state of investments in digital therapeutics, the barriers to adoption, challenging existing standards of care and how success in the sector requires patience and persistence. “Very recently
Adoption of digital therapeutics will require flexibility and patience Read More »
